SG11201703237VA - Humanized tau antibodies in alzheimer's disease - Google Patents
Humanized tau antibodies in alzheimer's diseaseInfo
- Publication number
- SG11201703237VA SG11201703237VA SG11201703237VA SG11201703237VA SG11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA SG 11201703237V A SG11201703237V A SG 11201703237VA
- Authority
- SG
- Singapore
- Prior art keywords
- alzheimer
- disease
- tau antibodies
- humanized tau
- humanized
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7047—Fibrils-Filaments-Plaque formation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Mycology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462081809P | 2014-11-19 | 2014-11-19 | |
| PCT/IB2015/002610 WO2016079597A1 (en) | 2014-11-19 | 2015-11-18 | Humanized tau antibodies in alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201703237VA true SG11201703237VA (en) | 2017-06-29 |
Family
ID=55411706
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201703237VA SG11201703237VA (en) | 2014-11-19 | 2015-11-18 | Humanized tau antibodies in alzheimer's disease |
Country Status (24)
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10501531B2 (en) | 2013-03-13 | 2019-12-10 | Prothena Biosciences Limited | Tau immunotherapy |
| EP3215191B1 (en) | 2014-11-05 | 2024-08-14 | Voyager Therapeutics, Inc. | Aadc polynucleotides for the treatment of parkinson's disease |
| MX388142B (es) * | 2014-11-19 | 2025-03-19 | Axon Neuroscience Se | Anticuerpos tau humanizados en enfermedad de alzheimer. |
| JP7194985B2 (ja) | 2016-05-02 | 2022-12-23 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| HUE060258T2 (hu) | 2016-05-02 | 2023-02-28 | Prothena Biosciences Ltd | Tau immunterápia |
| UA124148C2 (uk) | 2016-05-02 | 2021-07-28 | Протена Біосайенсіс Лімітед | Антитіла, що розпізнають тау |
| EP3583123A1 (en) | 2017-02-17 | 2019-12-25 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| JP7109467B2 (ja) * | 2017-03-28 | 2022-07-29 | ヤンセン ファッシンズ アンド プリベンション ベーフェー | タウに特異的に結合する結合分子 |
| US11958896B2 (en) | 2017-05-02 | 2024-04-16 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| WO2019023247A1 (en) | 2017-07-25 | 2019-01-31 | Immutics, Inc. | TREATMENT OF CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND |
| WO2019048017A1 (en) * | 2017-09-07 | 2019-03-14 | Danmarks Tekniske Universitet | METHODS FOR REMOVING NOX FROM A GAS STREAM CONTAINING MORE THAN ONE GAS COMPOUND |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| CN111757745B (zh) | 2018-02-01 | 2022-11-04 | Nkmax有限公司 | 产生天然杀伤细胞的方法和用于治疗癌症的组合物 |
| US12398201B2 (en) | 2018-02-19 | 2025-08-26 | New York University | Tau single domain antibodies |
| AU2019244481A1 (en) | 2018-03-28 | 2020-10-01 | Axon Neuroscience Se | Antibody-based methods of detecting and treating Alzheimer's disease |
| MX2020011458A (es) * | 2018-05-03 | 2020-12-07 | Washington University St Louis | Metodos de diagnostico y tratamiento basados en fosforilacion de tau especifica del sitio. |
| MX2020012077A (es) | 2018-05-15 | 2021-03-09 | Voyager Therapeutics Inc | Composiciones y metodos para el tratamiento de la enfermedad de parkinson. |
| WO2020077380A1 (en) * | 2018-10-17 | 2020-04-23 | The University Of Queensland | Methods and compositions for treating tauopathies |
| KR20210090184A (ko) * | 2018-11-08 | 2021-07-19 | 프로테나 바이오사이언시즈 리미티드 | 타우 인식 항체 |
| JP7630834B2 (ja) | 2019-03-03 | 2025-02-18 | プロセナ バイオサイエンシーズ リミテッド | タウ認識抗体 |
| TWI877179B (zh) * | 2019-06-27 | 2025-03-21 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
| US20220299527A1 (en) * | 2019-08-13 | 2022-09-22 | Washington University | Methods to detect mtbr tau isoforms and use thereof |
| AU2020345110A1 (en) | 2019-09-09 | 2022-03-24 | Axon Neuroscience Se | Biomarkers and treatments of alzheimer's disease and mild cognitive impairment |
| CA3161206A1 (en) * | 2019-12-12 | 2021-06-17 | Alector Llc | Methods of use of anti-cd33 antibodies |
| US20230201136A1 (en) * | 2020-02-28 | 2023-06-29 | Genemo, Inc. | Methods and materials for diagnosis and treatment of neuronal disorder |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| EP4217063A4 (en) * | 2020-09-22 | 2024-10-30 | Kathleen E. Clarence-Smith | PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF HUMAN HYPOCHOLINERGIC DISORDERS |
| CN113156134B (zh) * | 2020-11-26 | 2024-01-23 | 江苏荃信生物医药股份有限公司 | 用于检测人白介素23的elisa试剂盒及检测方法 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250044781A (ko) * | 2022-08-10 | 2025-04-01 | 주식회사 엔케이맥스 | 확장된 자연 살해 세포를 이용한 알츠하이머병 치료 방법 |
| EP4587470A1 (en) | 2022-09-15 | 2025-07-23 | Voyager Therapeutics, Inc. | Tau binding compounds |
| ES2998138R1 (es) * | 2023-07-28 | 2025-04-30 | Novartis Ag | Nuevos usos del omalizumab |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| HU196394B (en) | 1986-06-27 | 1988-11-28 | Richter Gedeon Vegyeszet | Process for preparing 2-halogenated ergoline derivatives |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
| US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| US5278299A (en) | 1991-03-18 | 1994-01-11 | Scripps Clinic And Research Foundation | Method and composition for synthesizing sialylated glycosyl compounds |
| US6797492B2 (en) | 1991-05-17 | 2004-09-28 | Merck & Co., Inc. | Method for reducing the immunogenicity of antibody variable domains |
| ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
| WO1993010260A1 (en) | 1991-11-21 | 1993-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases |
| US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP0652775B1 (en) | 1992-07-27 | 2000-04-19 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Targeting of liposomes to the blood-brain barrier |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| CU22615A1 (es) | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
| CA2142190C (fr) | 1995-02-14 | 1998-01-27 | Marc Lessard | Conduite d'exfiltration d'air use |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| IL122910A (en) | 1995-07-27 | 2002-05-23 | Genentech Inc | Stable isotonic protein formulation that has undergone lyophilization |
| PT871490E (pt) | 1995-12-22 | 2003-07-31 | Bristol Myers Squibb Co | Ligantes de hidrazona ramificada |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| EP2006303A1 (en) | 1997-04-09 | 2008-12-24 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for Beta-Amyloid ends, DNA encoding and methods of use thereof |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| AU3369999A (en) | 1998-04-02 | 1999-10-25 | Genentech Inc. | Antibody variants and fragments thereof |
| EP1071700B1 (en) | 1998-04-20 | 2010-02-17 | GlycArt Biotechnology AG | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| EP1214598B1 (en) | 1999-09-09 | 2006-05-17 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Screening for inhibitors of "paired helical filaments" |
| EP3070100B1 (en) | 2000-02-24 | 2021-07-07 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| US20020065259A1 (en) | 2000-08-30 | 2002-05-30 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| US20030083299A1 (en) | 2000-11-04 | 2003-05-01 | Ferguson Ian A. | Non-invasive delivery of polypeptides through the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| WO2003009815A2 (en) | 2001-07-25 | 2003-02-06 | Biomarin Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| NZ531219A (en) | 2001-08-03 | 2007-07-27 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| JP4308760B2 (ja) | 2002-07-12 | 2009-08-05 | アクソン・ニューロサイエンス・フォルシュングス−ウント・エントヴィックルングス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | トランケートｔａｕタンパク質 |
| EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| CA2507762C (en) | 2002-12-03 | 2013-02-05 | Blanchette Rockefeller Neurosciences Institute | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| KR20050101537A (ko) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| AU2004316290C1 (en) | 2003-11-06 | 2012-02-02 | Seagen Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| RU2402548C2 (ru) | 2004-05-19 | 2010-10-27 | Медарекс, Инк. | Химические линкеры и их конъюгаты |
| ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
| US8609097B2 (en) * | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| PL2625198T3 (pl) * | 2010-10-07 | 2015-12-31 | Ac Immune Sa | Przeciwciała rozpoznające fosfo-tau |
| SI2627672T1 (sl) | 2010-10-11 | 2018-10-30 | Biogen International Neuroscience Gmbh | Človeška protitelesa anti-tau |
| RS56852B1 (sr) | 2011-09-19 | 2018-04-30 | Axon Neuroscience Se | Terapija na osnovu proteina i dijagnoza patologije u kojoj posreduje tau u alchajmerovoj bolesti |
| SG11201406347TA (en) * | 2012-04-05 | 2014-11-27 | Ac Immune Sa | Humanized tau antibody |
| ES2816700T3 (es) | 2012-12-21 | 2021-04-05 | Biogen Ma Inc | Anticuerpos anti-tau humanos |
| MX388142B (es) * | 2014-11-19 | 2025-03-19 | Axon Neuroscience Se | Anticuerpos tau humanizados en enfermedad de alzheimer. |
-
2015
- 2015-11-18 MX MX2017006663A patent/MX388142B/es unknown
- 2015-11-18 AU AU2015348012A patent/AU2015348012B2/en active Active
- 2015-11-18 SG SG11201703237VA patent/SG11201703237VA/en unknown
- 2015-11-18 RU RU2017120688A patent/RU2730668C2/ru active
- 2015-11-18 SM SM20210055T patent/SMT202100055T1/it unknown
- 2015-11-18 LT LTEP15837211.0T patent/LT3221349T/lt unknown
- 2015-11-18 KR KR1020177016640A patent/KR20170126855A/ko not_active Ceased
- 2015-11-18 PL PL15837211T patent/PL3221349T3/pl unknown
- 2015-11-18 BR BR112017010498A patent/BR112017010498A2/pt not_active Application Discontinuation
- 2015-11-18 PT PT158372110T patent/PT3221349T/pt unknown
- 2015-11-18 CA CA2966964A patent/CA2966964A1/en not_active Abandoned
- 2015-11-18 RU RU2020126237A patent/RU2020126237A/ru unknown
- 2015-11-18 JP JP2017526550A patent/JP6830061B2/ja active Active
- 2015-11-18 WO PCT/IB2015/002610 patent/WO2016079597A1/en active Application Filing
- 2015-11-18 CN CN201580072454.2A patent/CN107428820B/zh active Active
- 2015-11-18 HR HRP20210124TT patent/HRP20210124T1/hr unknown
- 2015-11-18 HU HUE15837211A patent/HUE053239T2/hu unknown
- 2015-11-18 EP EP20198475.4A patent/EP3786182A1/en active Pending
- 2015-11-18 US US15/528,333 patent/US10160799B2/en active Active
- 2015-11-18 SI SI201531480T patent/SI3221349T1/sl unknown
- 2015-11-18 ES ES15837211T patent/ES2848376T3/es active Active
- 2015-11-18 EP EP15837211.0A patent/EP3221349B1/en active Active
- 2015-11-18 RS RS20210132A patent/RS61431B1/sr unknown
- 2015-11-18 DK DK15837211.0T patent/DK3221349T3/da active
-
2017
- 2017-04-25 IL IL251921A patent/IL251921B/en unknown
- 2017-05-19 MX MX2021014367A patent/MX2021014367A/es unknown
-
2018
- 2018-11-05 US US16/181,088 patent/US10745469B2/en active Active
-
2020
- 2020-03-18 JP JP2020047903A patent/JP6864763B2/ja active Active
- 2020-07-10 US US16/926,062 patent/US11319363B2/en active Active
- 2020-08-31 AU AU2020227007A patent/AU2020227007B2/en active Active
-
2021
- 2021-01-11 CY CY20211100012T patent/CY1123746T1/el unknown
- 2021-04-02 JP JP2021063583A patent/JP2021119774A/ja active Pending
- 2021-06-21 IL IL284250A patent/IL284250A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284250A (en) | Tau antibodies of human origin in Alzheimer's disease | |
| ZA201900373B (en) | Anti-tim-3 antibodies | |
| IL285722A (en) | Methods for treating Alzheimer's disease | |
| SG10201601719RA (en) | Anti-LAG-3 Antibodies | |
| GB201601073D0 (en) | Antibodies | |
| GB201621439D0 (en) | IL-11Ra Antibodies | |
| GB201610044D0 (en) | Antibodies | |
| IL252929A0 (en) | Anti-acth antibodies from humans and their use | |
| IL256097A (en) | Antibody epitope | |
| IL251837A0 (en) | Anti-endoglin antibodies and their uses | |
| GB201616699D0 (en) | Antibodies | |
| ZA201808317B (en) | Anti-tnfrsf25 antibodies | |
| GB201603291D0 (en) | Antibodies | |
| PT3101132T (pt) | Anticorpo humano anti-transtirretina | |
| GB201512596D0 (en) | Biomolecules involved in Alzheimer's disease | |
| PL3180356T3 (pl) | Ludzkie przeciwciało anty-fgfr4 | |
| IL267271A (en) | Antibodies against il-5 | |
| PT3484921T (pt) | Anticorpos anti-il-22r | |
| SG11201610594WA (en) | Anti-il4-il 13 bispecific antibodies | |
| SG11201703292VA (en) | ANTI HUMAN Gas6 MONOCLONAL ANTIBODY | |
| IL272676B (en) | Bispecific antibodies against il-4 and il-13 | |
| GB201622197D0 (en) | Antibodies | |
| GB201414038D0 (en) | Alzheimer's disease | |
| GB201620414D0 (en) | Antibodies | |
| GB201615224D0 (en) | Antibodies |